

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2002 (10.05.2002)

PCT

(10) International Publication Number
WO 02/36582 A1

(51) International Patent Classification⁷: **C07D 305/14**,
A61K 31/337, A61P 35/00

(21) International Application Number: PCT/PL01/00082

(22) International Filing Date: 19 October 2001 (19.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P.343615 31 October 2000 (31.10.2000) PL

(71) Applicants (*for all designated States except US*):
WARSZAWSKIE ZAKŁADY FARMACEUTYCZNE POLFA [PL/PL]; ul. Karolkowa 22/24, PL-01-207 Warszawa (PL). **INSTYTUT CHEMII ORGANICZNEJ PAN** [PL/PL]; ul. Kasprzaka 44/52, PL-01-244 Warszawa (PL). **AKADEMIA MEDYCZNA** [PL/PL]; ul. Gen. J. Hallera 107, PL-80-416 Gdansk (PL).

(72) Inventor: **JANICKI, Stanislaw**; Deceased.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SZNITOWSKA,**

Malgorzata [PL/PL]; ul. Szopinskiego 3 m 20, PL-80-772 Gdansk (PL). **KARAS, Wladyslaw** [PL/PL]; ul. Zamiejska 17 m 21, PL-03-580 Warszawa (PL). **MROCZEK, Zdzislaw** [PL/PL]; ul. Lazurowa 18 m 9, PL-01-315 Warszawa (PL). **TYRALA, Andrzej** [PL/PL]; ul. Wroclawska 16 m 59, PL-01-493 Warszawa (PL). **CZARNECKA, Iwona** [PL/PL]; ul. Nowodworska 20E, PL-03-133 Warszawa (PL).




(74) Agent: **WITKOWSKA, Teresa**; Warszawskie Zakłady Farmaceutyczne Polfa, ul. Karolkowa 22/24, PL-01-207 Warszawa (PL).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: STABLE PHARMACEUTICAL FORM OF AN ANTICANCER DRUG



(57) Abstract: The stable pharmaceutical form of the anti-cancer drug containing paclitaxel of the Fig. 1, according to the invention, is characterised in that it is a stable form of the active substance of a large surface, amorphous, possibly with some fine-crystalline additive. According to the invention, the method for production of the stable pharmaceutical form of the anticancer drug consists in dissolution of crystalline paclitaxel in a neutral organic solvent selected from the group comprising acetonitrile, dioxane, ethanol, or a mixture of those solvents, with possible addition of water, providing that the control of individual solvents in the mixture is in the range of 5 % to 95 %, while the content of water is in the range of 0 to 60 %; the resulting solution is possibly filtered, frozen, and solvents are removed by sublimation under reduced pressure, at a low temperature, and thereafter the preparation is possibly distributed into doses in conditions assuring its sterility.



IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

STABLE PHARMACEUTICAL FORM OF AN ANTICANCER DRUG

The present invention concerns a stable pharmaceutical form of an anticancer drug and a method for production of a stable pharmaceutical form of an anticancer drug containing exclusively, or in addition to other active substances, the chemical compound insoluble in water, named paclitaxel, presented by the Fig. 1.

Paclitaxel of the Fig. 1 is a known chemical compound isolated from the bark of the tree *Taxus brevifolia* or obtained through chemical synthesis. This compound is used in medicine in the treatment of malignant neoplasms resistant to other methods of therapy (Slichenmyer WJ, Von Hoff DD. New natural products in cancer chemotherapy. J.Clin. Pharmacol.1990; 30: 770-88, Rowinnsky EK et. al. Taxol: a novel investigational antimicrotubule agent, J.Natl. Cancer Inst. 1990; 82: 1247-59, Long HJ, Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin. Proc. 1994; 69:

Donehower RC. Paclitaxel (Taxol). N.Engl. J.Med. 1995, 332: and other papers).

In cancer therapy, paclitaxel is administered intravenously, thus it is necessary to make solutions of appropriate concentration in biocompatible solvent systems.

Very slight solubility of paclitaxel in water makes impossible its direct administration in classical, commonly used infusion fluids. Therefore, the only hitherto used commercial forms of pharmaceuticals containing paclitaxel are the "basic" solutions of this substance in a mixture of a polar solvent and a surface-active substance, which cannot be injected to a patient directly, but only after prior dilution with an infusion fluid.

The best-known double-solvent system used for making the "basic" solutions of paclitaxel is a mixture of polyethoxylated castor oil, known under the trade name of Cremophor EL, and ethyl alcohol. The characteristic feature of those solutions is that after being diluted with an infusion fluid they can precipitate. Moreover, chemical stability of paclitaxel in such solutions is low. Already after 2 months of storage at the temperature of 25°C, 10% reduction in the active substance content was observed, and after 22 months the content of paclitaxel was only 67% of its initial quantity. The rate of decomposition at elevated temperatures was

considerably higher. Instability of paclitaxel in such solutions is connected with the chemical properties of Cremophor EL and the presence of even a small quantity of water in ethyl alcohol. It is obvious that such a preparation has very limited applications and its administration to a patient involves a real risk consequential to the administration of too low a dose of the drug due to its decomposition.

In patent no. 176826, a procedure partially eliminating the above-mentioned disadvantages was proposed. It consisted in complex commercial purification of Cremophor EL so as to eliminate those chemical properties of paclitaxel that compromised its stability, or in addition of an acid so as to reduce the solvent concentration of carboxylic anions affecting the substance stability, or in utilisation of anhydrous ethyl alcohol. The solutions obtained in that way were significantly more stable and they could be stored for a longer period of time at room temperature without an evident loss of activity. However, after those solutions are diluted with an infusion fluid there is a risk of precipitation, and that is why it is necessary to use an infusion set provided with an appropriate filter.

However, the above procedure does not eliminate a serious disadvantage of thus produced pharmaceutical, connected with the application of Cremophor EL whose presence in medicinal products

administered intravenously may in some cases result in the risk of anaphylactic shock (Rowinnsky EK, et. al. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 1990; 82: 1247-59).

Furthermore, the presence of ethyl alcohol in a medicinal product when dosage regimens requiring administration of large quantities of the drug are applied may lead to intoxication symptoms.

In the patent description 169372, the method was presented for production of paclitaxel solutions of higher concentrations of the active substance, which reduces the harmful action of Cremophor EL. The method also allows to eliminate nearly completely ethyl alcohol from the preparation, and thus to reduce considerably the harmful action of that second component of the drug.

Unexpectedly, it turned out that the application of the new pharmaceutical form obtained by the method according to the invention solved all the above-mentioned problems with the stability of the paclitaxel-containing medicine and allowed to eliminate some harmful components used up to now.

According to the present invention, the stable pharmaceutical form of the anticancer drug containing paclitaxel of the Fig. 1 is characterised in that it is a solid, amorphous form of the active substance, of a

large surface, possibly with some fine-crystalline additive.

According to the invention, the method for production of the stable pharmaceutical form of the anticancer drug consists in dissolution of crystalline paclitaxel in a neutral organic solvent selected from the group comprising acetonitrile, dioxane, ethanol, or a mixture of those solvents, with possible addition of water, providing that the content of individual solvents in the mixture is in the range of 5% to 95%, while the content of water is in the range of 0 to 60%; the resulting solution is possibly filtered, frozen, and solvents are removed by sublimation under reduced pressure, at a low temperature, and thereafter the preparation is possibly distributed into doses in conditions assuring its sterility.

Preferably, in the method according to the invention, the possibly filtered solution of paclitaxel is first dosed into containers, and then it is frozen, and solvents are removed by sublimation under reduced pressure, at a low temperature.

In the method according to the invention, solvent removal by sublimation is preferably performed at the temperature ranging from -60°C to $+50^{\circ}\text{C}$.

The pharmaceutical form of the anticancer drug according to the invention is very stable chemically and at the same time freely soluble in various biocompatible

biocompatible solvents systems, which makes possible its administration to the patient.

Paclitaxel isolated from *Taxus brevifolia* or obtained through chemical syntheses is a crystalline substance as presented in Fig.2, whose heat of dissolution in ethyl alcohol is 66.6 J/g.

Unexpectedly, it turned out that the substance prepared by the method according to the invention was a form where the amorphous structure as presented in Fig. 3 was prevalent and whose heat of dissolution in ethanol, equal to 32.4 J/g, was twice lower in comparison with the crystalline form.

Because the drug is dissolved immediately before its administration, there are no complications connected with the stability of thus prepared solutions, while such complications are observed in the case of the finished formulation in the form of the "basic" solutions available to date.

Furthermore, this stable form of paclitaxel does not limit the selection of therapeutically appropriate solvents.

The drug prepared in the above manner is stable and it can be dissolved immediately before its administration in various solvent systems containing such components as polyoxyethylene glycols, polysorbates, polyoxyethylated fatty acids, ethanol, phospholipid fractions, lecithines, oil-in-water

emulsions, propylene glycol, benzyl alcohol, dimethylacetamide, methylacetamide, saccharide esters and ethers of fatty acids, ethylene oxide copolymer, propylene oxide copolymer, sodium glycocholate, and others. The obtained solutions can be administered directly or following their dilution with the appropriate infusion fluid.

Performance of the invention is presented by the following examples.

Example I.

1500 mg of paclitaxel were dissolved in 100 ml of 1,4-dioxane. The resulting solution was sterilised in aseptic conditions by filtering through a 0.2 μm teflon filter. Then the solution was filled at the doses of 2 ml into 20-ml sterile glass vials. The vials were provided with sterile rubber stoppers for freeze-drying. The vials were placed in a freeze dryer provided with a device for closing the vials after the end of the sublimation drying process. The solutions were frozen to the temperature of -40°C . The drying process was conducted at the pressure of 0.1 mbar with gradual increase of the plate temperature up to $+30^{\circ}\text{C}$. After the drying process was terminated, the vials were closed and the vacuum was reduced. After the vials were taken out of the freeze drier, they were capped and provided with the corresponding labels. Each vial contained 30 mg of

paclitaxel. The medicine obtained in this way contains not more than 380 ppm of dioxane and is stable for at least 3 years.

Example II.

1500 mg of paclitaxel were dissolved in 80 ml of 1,4-dioxane. 20 ml of water were added. The resulting solution was sterilised in aseptic conditions by filtering through a 0.2 μ m teflon filter. Then the solution was filled at the doses of 2 ml into 20-ml sterile glass vials. The vials were provided with sterile rubber stoppers for freeze-drying. The vials were placed in a freeze dryer provided with a device for closing the vials after the end of the sublimation drying process. The solutions were frozen to the temperature of -40°C . The drying process was conducted at the pressure of 0.1 mbar with gradual increase of the plate temperature up to $+30^{\circ}\text{C}$. After the drying process was terminated, the vials were closed and the vacuum was reduced. After the vials were taken out of the freeze drier, they were capped and provided with the corresponding labels. Each vial contained 30 mg of paclitaxel. The medicine obtained in this way contains not more than 380 ppm of dioxane and is stable for at least 3 years.

Example III.

1500 mg of paclitaxel were dissolved in 50 ml of 1,4-dioxane. 50 ml of water were added. The resulting solution was sterilised in aseptic conditions by filtering through a 0.2 µm teflon filter. Then the solution was filled at the doses of 2 ml into 20-ml sterile glass vials. The vials were provided with sterile rubber stoppers for freeze-drying. The vials were placed in a freeze dryer provided with a device for closing the vials after the end of the sublimation drying process. The solutions were frozen to the temperature of -40°C. The solvent sublimation process was conducted at the pressure of 0.1 mbar with gradual increase of the plate temperature up to +30°C. After the drying process was terminated, the vials were closed and the vacuum was reduced. After the vials were taken out of the freeze drier, they were capped and provided with the corresponding labels. Each vial contained 30 mg of paclitaxel. The medicine obtained in this way contains not more than 380 ppm of dioxane and is stable for at least 3 years.

Example IV.

30 ml of ethanol were added to 40 ml of 1,4-dioxane. 1500 mg of paclitaxel were dissolved in that solvent. 30 ml of water were added. The resulting solution was sterilised in aseptic conditions by filtering through a 0.2 µm teflon filter. Then the solution was filled at the

doses of 2 ml into 20-ml sterile glass vials. The vials were provided with sterile rubber stoppers for freeze-drying. The vials were placed in a freeze dryer provided with a device for closing the vials after the end of the sublimation drying process. The solutions were frozen to the temperature of -50°C . The drying process was conducted at the pressure of 0.1 mbar with gradual increase of the plate temperature up to $+40^{\circ}\text{C}$. After the drying process was terminated, the vials were closed and the vacuum was reduced. After the vials were taken out of the freeze drier, they were capped and provided with the corresponding labels. Each vial contained 30 mg of paclitaxel. The medicine obtained in this way contains not more than 380 ppm of dioxane, 0.5% of ethanol, and is stable for at least 3 years.

Example V.

In the same manner as in Example I, 1500 mg of paclitaxel were dissolved, respectively, in 100 ml of various solvents whose composition is presented in the table below:

	Acetonitrile	1,4-dioxane	Ethanol	Water
a	5%	90%	0%	5%
b	0%	80%	10%	10%
c	10%	60%	0%	30%
d	0%	50%	20%	30%
e	10%	80%	5%	5%

The preparations obtained as a result of freeze-drying of the solvents from a to e had an amorphous form and were stable for 3 years.

Example VI.

5 ml of the sterile solvent consisting of 1980 mg of anhydrous ethanol and 2635 mg of polyoxyethylated castor oil were added to the freeze-dried substance obtained according to Examples I – V. Paclitaxel is immediately completely dissolved. The resulting solution is stable for at least 2 years at the temperature of +4°C and for at least 3 months at room temperature. This solution, which is a concentrate, is added to the appropriate infusion fluid as presented in Example VIII.

Example VII.

5 ml of the sterile solvent consisting of 300 mg of polysorbate 80, 3400 mg of pharmacopoeial polyoxyethylene glycol 300, and 1300 mg of anhydrous ethanol were added to the freeze-dried substance obtained according to Examples I – V. Paclitaxel was immediately completely dissolved. The resulting solution is stable at room temperature for at least 8 hours. This solution, which is a concentrate, is added to the appropriate infusion fluid as presented in Example VIII.

Example VIII.

The concentrate obtained in Examples VI and VII was diluted its intravenous administration to the patient so as to obtain the final paclitaxel concentration of 0.3 - 1.2 mg/ml. The following were used for dilution: 0.9% sodium chloride solution, 5% glucose solution, and other infusion fluids such as the Ringer solution, the mixture of 5% glucose solution with 0.9% sodium chloride solution, the mixture of 5% glucose solution with the Ringer solution, 5% sorbitol solution, 6% dextrane solution, 10% or 20% or 30% oil-in-water emulsion for parenteral nutrition. Such solutions are stable at room temperature for at least 6 hours, which makes possible their safe administration to the patient.

Example IX.

150 mg of the freeze-dried substance obtained according to Examples I – V were added to 500 ml of 30% soybean oil emulsion for intravenous infusion. The obtained fluid was mixed carefully until paclitaxel was completely dissolved. The resulting emulsion is stable at room temperature for at least 8 hours and it can be given to a patient by the intravenous route.

Claims

1. The stable pharmaceutical form of an anticancer drug containing paclitaxel of the Fig.1 characterised in that it is a solid, amorphous form of the active substance, of a large surface, possibly with some fine-crystalline additive.
2. The method for obtaining a stable pharmaceutical form of an anti-cancer drug characterised in that crystalline paclitaxel is dissolved in a neutral organic solvent selected from the group comprising acetonitrile, dioxane, ethanol, or a mixture of those solvents, with possible addition of water, providing that the content of several solvents in the mixture is in the range of 5% to 95%, while the content of water is in the range of 0 to 60%; the resulting solution is possibly filtered, frozen, and solvents are removed by sublimation under reduced pressure, at a low temperature, and thereafter the preparation is possibly distributed into doses in conditions assuring its sterility.

3. The method according to Claim 2, characterised in that the paclitaxel solution filtered through a sterilising filter is first dosed into containers in aseptic conditions and thereafter is frozen and solvents are removed by sublimation under reduced pressure, at a low temperature.
4. The method according to Claim 1 or 2 characterised in that solvent removal by sublimation is performed at the temperature in the range of -60°C to $+50^{\circ}\text{C}$.
5. The method according to Claim 1 or 2 characterised in that the content of several solvents in the mixture is from 5% to 95% and the content of water is from 1% to 60%.




fig. 1

2/2




fig.2




fig.3

INTERNATIONAL SEARCH REPORT

Inte 1al Application No

PCT/PL 01/00082

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D305/14 A61K31/337 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 717 041 A (BRISTOL-MYERS) 19 June 1996 (1996-06-19) page 6; claims	1
P,X	CHEMICAL ABSTRACTS, vol. 136, no. 1, 2002 Columbus, Ohio, US; abstract no. 11026r, LEE, J.H.: "PREPARATION A. CHARACTERISATION OF SOLVENT INDUCED DIHYDRATE, ANHYDROUS A. AMORPHOUS PACLITAXEL." page 1219; XP002190101 abstract & BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 22, no. 8, 2001, pages 925-8, SOUTH-KOREA	1

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

15 February 2002

Date of mailing of the international search report

07/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT
information on patent family members

Inte 1al Application No
PCT/PL 01/00082

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 717041	A	19-06-1996	
		AU 699542 B2	03-12-1998
		AU 4035595 A	20-06-1996
		CA 2163837 A1	14-06-1996
		EP 0717041 A1	19-06-1996
		JP 8208636 A	13-08-1996
<hr/>			